JNJ-6143 Delivers Early Tumor Responses, but Proof Is Still Ahead

Johnson & Johnson's experimental prostate-cancer pill JNJ-6143 produced tumor responses in a small Phase 1 study, giving the company an encouraging first clinical readout on technology it acquired with Halda Therapeutics. The result is meaningful for the pipeline, but the study is too early and too small to establish a commercial outcome.

Among 16 patients with measurable disease, 12, or 75%, had a confirmed complete or partial response. That corrects a lower 69% figure in the secondary source. In the 50-milligram once-daily cohort, 77% of 38 patients had a confirmed decline of at least 50% in prostate-specific antigen, and 48% had a decline of at least 90%. PSA is a blood marker used to monitor prostate cancer, while imaging response measures visible tumors, so the two endpoints should not be treated as interchangeable.

The patients had advanced disease that had progressed after prior treatment and had received a median of four previous therapies, including chemotherapy and PSMA-targeted radioligand therapy. At a median follow-up of 5.6 months, 71% of patients on the 50-milligram dose remained on treatment. The most common treatment-related adverse events were elevated cholesterol at 18%, nausea at 16% and elevated triglycerides at 16%. Four patients interrupted dosing, one reduced the dose and one discontinued because of adverse events.

JNJ-6143 is an oral RIPTAC molecule designed to bring together BRD4, a protein needed for cell survival, and the androgen receptor, which is highly expressed in prostate-cancer cells. That targeted interaction is intended to disrupt cancer-cell function and trigger cell death. Johnson & Johnson selected 50 milligrams once daily for further development and plans a Phase 2 study in metastatic prostate cancer.

The program came from Johnson & Johnson's $3.05 billion cash acquisition of Halda Therapeutics, completed in December 2025. That price covered the RIPTAC platform as well as JNJ-6143 and earlier candidates in other solid tumors, so the Phase 1 readout is an initial test of a broader technology bet rather than a standalone asset valuation.

The next evidence will matter more than the headline response rate. Phase 1 trials primarily establish dose, safety and early activity; they lack the size and comparative design needed to show whether a drug improves survival or outperforms existing care. Investors should watch durability, outcomes in a larger population, safety with longer exposure and whether the Phase 2 study confirms activity across difficult molecular subgroups. For now, JNJ-6143 strengthens the oncology pipeline without materially changing near-term earnings.